CA2625981A1 - Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof - Google Patents

Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof Download PDF

Info

Publication number
CA2625981A1
CA2625981A1 CA002625981A CA2625981A CA2625981A1 CA 2625981 A1 CA2625981 A1 CA 2625981A1 CA 002625981 A CA002625981 A CA 002625981A CA 2625981 A CA2625981 A CA 2625981A CA 2625981 A1 CA2625981 A1 CA 2625981A1
Authority
CA
Canada
Prior art keywords
sequence
gse
nucleotide sequence
cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002625981A
Other languages
English (en)
French (fr)
Inventor
Rosario Perona Abellon
Rosario Machado Pinilla
Leandro Sastre Garzon
Isabel Sanchez Perez
Jose Ramon Murguia Ibanez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Universitat Politècnica de València
Autonomous University of Madrid
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2625981A1 publication Critical patent/CA2625981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
CA002625981A 2005-10-14 2006-10-11 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof Abandoned CA2625981A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200502511A ES2325431B1 (es) 2005-10-14 2005-10-14 Secuencia de nucleotidos y peptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtencion, composiciones terapeuticas y sus aplicaciones.
ESP200502511 2005-10-14
PCT/ES2006/070152 WO2007090911A1 (es) 2005-10-14 2006-10-11 Secuencia de nucleótidos y péptidos gse 24.2 de la disquerina inductores de la actividad telomerasa, procedimiento de obtención, composiciones terapéuticas y sus aplicaciones

Publications (1)

Publication Number Publication Date
CA2625981A1 true CA2625981A1 (en) 2007-08-16

Family

ID=38344881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002625981A Abandoned CA2625981A1 (en) 2005-10-14 2006-10-11 Sequence of nucleotides and peptides gse 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof

Country Status (10)

Country Link
US (2) US9074194B2 (enExample)
EP (1) EP1947175B1 (enExample)
JP (1) JP5560398B2 (enExample)
AT (1) ATE469212T1 (enExample)
CA (1) CA2625981A1 (enExample)
DE (1) DE602006014574D1 (enExample)
DK (1) DK1947175T3 (enExample)
ES (2) ES2325431B1 (enExample)
PT (1) PT1947175E (enExample)
WO (1) WO2007090911A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2334736B1 (es) * 2007-11-23 2011-02-02 Consejo Superior De Investigaciones Cientificas (Titular Al 90%) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
US20160051485A1 (en) * 2013-02-05 2016-02-25 Consejo Superior De Investigaciones (Csic) Biodegradable Bionanoparticles for Releasing the GSE24-2 Peptide, Method for the Production Thereof, and Use of Same
EP3061815B1 (en) * 2013-10-25 2020-02-19 Consejo Superior de Investigaciones Cientificas (CSIC) Peptides derived from gse 24.2 for treating diseases caused by oxidative stress and damage to dna
KR20220022126A (ko) * 2019-05-02 2022-02-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tert 활성화 치료요법을 포함하는 방법 및 조성물
WO2024194500A1 (es) 2023-03-17 2024-09-26 Consejo Superior De Investigaciones Científicas (Csic) Péptido derivado de gse24.2 y usos del mismo
ES2989543A1 (es) * 2023-05-22 2024-11-26 Alodia Farm S L U Peptidos para su uso en la prevencion y/o tratamiento de radiodermitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE19817118C1 (de) * 1998-04-17 1999-10-28 Deutsches Krebsforsch Dyskerin und dafür codierende DNA-Moleküle, diese enthaltende Vektoren, Antikörper gegen Dyskerin und die Verwendung dieser Gegenstände

Also Published As

Publication number Publication date
DK1947175T3 (da) 2010-09-27
US20150337022A1 (en) 2015-11-26
ES2360238T3 (es) 2011-06-02
DE602006014574D1 (de) 2010-07-08
JP2009511036A (ja) 2009-03-19
US9074194B2 (en) 2015-07-07
EP1947175B1 (en) 2010-05-26
ES2325431B1 (es) 2010-06-28
EP1947175A1 (en) 2008-07-23
ES2325431A1 (es) 2009-09-03
WO2007090911A1 (es) 2007-08-16
US20090202503A1 (en) 2009-08-13
US9587002B2 (en) 2017-03-07
PT1947175E (pt) 2010-09-02
JP5560398B2 (ja) 2014-07-23
ATE469212T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
US9587002B2 (en) Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
KR20010020601A (ko) 척추 동물 텔로머라제 유전자 및 단백질과 이의 용도
JP2013056876A (ja) 抗炎症化合物及びその利用
CA2666536A1 (en) Compositions and methods of using chondroitinase abci mutants
JP5581485B2 (ja) Ｅｃ−ｓｏｄの新規な用途及びその製造方法
EP0896055A2 (en) Apoptosis inducing protein and gene encoding the same
KR102127218B1 (ko) 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
ES2334736B1 (es) Uso de agentes inductores gse24.2 para la elaboracion de composiciones farmaceuticas para el tratamiento de enfermedades que cursan con senescencia celular.
KR100399982B1 (ko) Ａｓｋ１과 결합하는 ｃａｄ의 선택적인 저해제로서아폽토시스를 억제하는 신규한 마우스 ｃｉａ 단백질,ｃｉａ 유전자 및 그의 용도
Perona Abellón et al. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof
SÁNCHEZ PÉREZ TELOMERASE ACTIVITY, METHOD FOR OBTAINING SAME, THERAPEUTIC COMPOSITIONS
KR102241134B1 (ko) Fgf2 또는 api5 유래 펩타이드를 발현하는 항암 바이러스 및 이의 용도
Lepetit et al. The cloning and characterization of a cDNA encoding Xenopus laevis DNA ligase I
WO2003024997A1 (en) Telomerase inhibitory peptides and uses thereof
KR100740342B1 (ko) Ｐｋｃ 델타의 ｈｓｐｂ1 결합부위를 포함하는 암 치료용조성물
US20030105008A1 (en) Geminin and Orc3N inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
US20090047672A1 (en) Telomerase RNA Subunit and Methods of Use Thereof
KR101826249B1 (ko) 융합 단백질 및 이를 포함하는 세포주기 조절제
AU2005253643B2 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
JP2007169223A (ja) アポトーシス促進剤およびそれを用いた医薬製剤
JP2003506081A (ja) ＮＦ−κＢ活性化に関与するプロテインキナーゼＣ相互作用性タンパク質
Suzanne Lewis Genetic modification of the human mitotic clock by telomerase: a matter of life and death.
KR20090111728A (ko) Ｊｎｋ1을 유효성분으로 포함하는 ｎｒｌ-매개 안구질환의예방 및 치료용 약학적 조성물
AU2002325676A1 (en) Telomerase inhibitory peptides and uses thereof
CA2569687A1 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20200831